Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Definium Therapeutics, Inc. - Common Shares
(NQ:
DFTX
)
35.89
+0.27 (+0.76%)
Delayed Quote
Updated: 1:43 PM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Definium Therapeutics, Inc. - Common Shares
< Previous
1
2
3
Next >
Definium Therapeutics Announces New Employee Inducement Grants
September 28, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression
↗
September 24, 2026
Definium Therapeutics (NASDAQ:DFTX) Chief Medical Officer Dan Karlin said the company’s recent Phase III results for DT120 showed statistically significant improvements in generalized anxiety disorder,...
Via
MarketBeat
Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study
↗
September 19, 2026
Definium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Panorama, its second Phase III study of DT120 ODT 100 mcgs in generalized anxiety disorder, or GAD. The company said the...
Via
MarketBeat
Definium Therapeutics (NASDAQ:DFTX) Slides After Q2 Loss Misses Estimates on Warrant Charge
↗
August 06, 2026
Via
Chartmill
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
September 14, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
September 14, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
September 13, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
September 10, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
September 08, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
August 31, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
August 26, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
August 17, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study
↗
August 13, 2026
Definium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Voyage, its Phase III study evaluating a single 100 mcg dose of DT120 ODT for generalized anxiety disorder, or GAD. The...
Via
MarketBeat
Wondering what's happening in today's pre-market session?
↗
August 12, 2026
Via
Chartmill
Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
August 12, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Q2 Earnings Call Highlights
↗
August 06, 2026
Definium Therapeutics (NASDAQ:DFTX) said it expects to report top-line results from its Phase III VOYAGE study of DT120 ODT in generalized anxiety disorder during the week of Aug. 10, following...
Via
MarketBeat
Topics
Earnings
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
August 06, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
August 05, 2026
Issued on behalf of Helus Pharma (Nasdaq: HELP)
From
USA News Group
Via
GlobeNewswire
Definium Therapeutics Announces New Employee Inducement Grants
August 03, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
July 30, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
July 20, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
July 16, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
July 14, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
July 06, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
June 30, 2026
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END
Via
FinancialNewsMedia
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
June 30, 2026
Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity
From
MarketNewsUpdates.com
Via
GlobeNewswire
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
June 25, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
June 23, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics, Inc. Announces Proposed Public Offering
June 22, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Top movers analysis one hour before the close of the markets on 2026-06-22: top gainers and losers in today's session.
↗
June 22, 2026
Via
Chartmill
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
